Liquidia Corporation $LQDA Stock Sold by Signaturefd LLC

Signaturefd LLC reduced its holdings in shares of Liquidia Corporation (NASDAQ:LQDA) by 79.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,119 shares of the company’s stock after selling 24,191 shares during the quarter. Signaturefd LLC’s holdings in Liquidia were worth $185,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in LQDA. Nisa Investment Advisors LLC raised its stake in shares of Liquidia by 13.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,634 shares of the company’s stock valued at $80,000 after acquiring an additional 320 shares during the period. Quantinno Capital Management LP lifted its holdings in shares of Liquidia by 3.6% during the 1st quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock valued at $648,000 after acquiring an additional 589 shares in the last quarter. Yousif Capital Management LLC lifted its holdings in shares of Liquidia by 4.1% during the 3rd quarter. Yousif Capital Management LLC now owns 20,008 shares of the company’s stock valued at $605,000 after acquiring an additional 794 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of Liquidia by 5.4% during the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock valued at $1,405,000 after acquiring an additional 900 shares in the last quarter. Finally, Swiss National Bank boosted its position in Liquidia by 1.3% during the 1st quarter. Swiss National Bank now owns 120,400 shares of the company’s stock worth $4,544,000 after purchasing an additional 1,600 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Price Performance

Shares of LQDA stock opened at $41.85 on Tuesday. The firm has a fifty day simple moving average of $52.46 and a 200-day simple moving average of $54.32. The company has a market capitalization of $3.75 billion, a PE ratio of 33.37, a price-to-earnings-growth ratio of 0.40 and a beta of 0.61. Liquidia Corporation has a twelve month low of $22.21 and a twelve month high of $93.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The firm had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same period last year, the firm earned ($0.49) EPS. The business’s quarterly revenue was up 1842.1% on a year-over-year basis. Equities research analysts anticipate that Liquidia Corporation will post 2.05 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Roger Jeffs sold 32,744 shares of Liquidia stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $932,549.12. Following the sale, the chief executive officer directly owned 1,125,848 shares of the company’s stock, valued at approximately $32,064,151.04. The trade was a 2.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jason Adair sold 73,631 shares of the business’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $69.09, for a total value of $5,087,165.79. Following the completion of the transaction, the insider owned 174,606 shares in the company, valued at approximately $12,063,528.54. This trade represents a 29.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 566,579 shares of company stock worth $25,746,120 over the last quarter. Company insiders own 25.60% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on LQDA shares. Needham & Company LLC lowered their price target on Liquidia from $72.00 to $58.00 and set a “buy” rating for the company in a report on Wednesday, October 14th. Zacks Research cut Liquidia from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 22nd. Jefferies Financial Group upgraded Liquidia to a “strong-buy” rating in a research note on Thursday, October 1st. Royal Bank Of Canada set a $65.00 target price on Liquidia in a research report on Thursday, October 15th. Finally, Lifesci Capital upgraded Liquidia from a “hold” rating to an “outperform” rating and set a $59.00 target price for the company in a research note on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $72.85.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler.